The EHMT1 knockout K-562 polyclonal cells represent a CRISPR/Cas9-edited pooled population of K-562 chronic myelogenous leukemia cells carrying targeted disruption of the EHMT1 gene, generating a heterogeneous loss-of-function model for the histone methyltransferase EHMT1. This polyclonal format preserves the genetic diversity of independent editing events, enabling robust comparative studies of EHMT1-dependent functions while avoiding clonal selection bias.
K-562 is a widely utilized human immortalized myelogenous leukemia cell line derived from a 53-year-old female patient with chronic myelogenous leukemia in blast crisis. The cells harbor the BCR-ABL fusion oncogene, which drives constitutive tyrosine kinase activity and serves as a therapeutic target, making this line a central model for studying CML pathogenesis, hematopoietic differentiation, and cellular responses to tyrosine kinase inhibitors and other anticancer agents.
EHMT1 (euchromatic histone-lysine N-methyltransferase 1) functions as a histone methyltransferase that specifically catalyzes dimethylation of histone H3 at lysine 9 (H3K9me2), a hallmark of facultative heterochromatin and transcriptionally repressed chromatin. It forms a corepressor complex with its paralog EHMT2 (G9a), and this complex interacts with HP1 proteins, DNMT1, and PCNA, coupling histone methylation with DNA methylation and replication to maintain epigenetic silencing. EHMT1 expression is regulated by transcription factors such as E2F1 and REST, and it exerts repressive activity on key downstream targets including the tumor suppressors p16INK4a and p14ARF, as well as Hox gene clusters. Through these interactions, EHMT1 plays a critical role in developmental gene regulation and cell cycle control.
In the K-562 leukemia background, disruption of EHMT1 offers a powerful system to dissect the contribution of H3K9me2-mediated silencing to BCR-ABL-driven oncogenesis and to the epigenetic landscape of hematological malignancies. Given EHMT1??s role in repressing tumor suppressors such as p16INK4a and p14ARF, its loss may derepress these loci, potentially altering proliferation rates, differentiation capacity, or drug sensitivity profiles. This model also enables investigation into the interplay between EHMT1 and BCR-ABL signaling, as well as the broader epigenetic rewiring that accompanies leukemic transformation.
The EHMT1 knockout K-562 polyclonal cells are suited for a range of experimental applications, including chromatin immunoprecipitation (ChIP-qPCR) to assess genome-wide H3K9me2 changes, western blotting to profile histone methylation marks, RT-qPCR or RNA-seq to quantify derepression of target genes such as p16INK4a and Hox genes, and functional assays such as cell proliferation and drug sensitivity screens. These cells also provide a relevant platform for validating EHMT1 as a therapeutic target in cancer and for modeling epigenetic dysregulation in developmental disorders like Kleefstra syndrome. For additional information or customized services, please contact Ascent Research.
